Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study is being done to help researchers understand more about prostate cancer that has
spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to
better understand the effect of an experimental drug called XL184 (or cabozantinib) on bone
disease. The other purposes of the study are to better understand the effect of XL184 on
prostate cancer progression, bone pain, and on any cancer cells that patients may have
circulating within the blood (called circulating tumor cells)